MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HAKALA, M. T.
Right arrow Articles by SUOLINNA, E.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HAKALA, M. T.
Right arrow Articles by SUOLINNA, E.-M.

Molecular Pharmacology, Vol 2, 465-480, Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics

Specific Protection of Folate Reductase Against Chemical and Proteolytic Inactivation

MAIRE T. HAKALA 1 and ELSE-MAJ SUOLINNA 1

1 Department of Experimental Therapeutics, Roswell Park Memorial Institute, Buffalo, New York 14203

Folate reductase of amethopterin resistant S-180 cells (AT/3000), grown in vitro, is inactivated by o-phenanthroline, EDTA, p-chloromercuribenzoate, iodoacetamide, trypsin, subtilisin, elastase, and carboxypeptidase B, but not by carboxypeptidase-A or leucineaminopeptidase. The enzymatic activity and the number of amethopterin binding sites were always lost in parallel fashion. When substrates or coenzymes were present, complete protection of the enzymic activity and of the amethopterin binding sites against all these agents was observed. Competitive inhibitors, 2,4-diaminopurine and -pyrimidine, which mimic just a small portion of the substrate molecule, also protected completely against o-phenanthroline and against the proteolytic enzymes but poorly against SH-reagents. It is suggested that folate (probably the pyrimidine portion of it) and TPNH are bound to the enzyme in the proximity of a metal and SH-groups. The protection against the proteolytic digestions is probably provided through conformational changes in the enzyme. No major proteolytic breakdown of the enzyme molecule, as a whole, was observed when folate reductase was complexed with amethopterin.

It is suggested that the intracellular presence of substrate, coenzyme or competitive inhibitor of folate reductase may alter the turnover of this enzyme by preventing the proteolytic breakdown. In certain circumstances this could lead to an increase in the folate reductase content of cells and tissues. Also, it is concluded that folate reductase can form binary complexes with both the substrate and the coenzyme. Thus, the prior presence of coenzyme on the enzyme surface is not necessary for the attachment of the substrate and vice versa. Since the concentrations of folate, TPNH, and TPN which afforded 50% protection were of the same order of magnitude as the respective Km values, it seems that the presence of one on the enzyme surface does not affect the affinity to the other.

Note:
ACKNOWLEDGMENTS The authors wish to express their appreciation to Mrs. L. Kenny and Miss D. Sugg for their skillful technical assistance. This investigation was supported in part by research grant CA-04175 from the National Cancer Institute of the U.S. Public Health Service.

Submitted on June 17, 1966







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics